UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153

Journal of clinical oncology, 2020-11, Vol.38 (33), p.3863-3873

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.914-947

2020

Link zum Volltext

Verfügbarkeit prüfen

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement

American journal of respiratory and critical care medicine, 2019-09, Vol.200 (6), p.e31-e43

2019

Link zum Volltext

Verfügbarkeit prüfen

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

Cancer science, 2020-12, Vol.111 (12), p.4510-4525

2020

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib plus Ramucirumab: The Best of Both Worlds?

Clinical cancer research, 2021-02, Vol.27 (4), p.905-907

Garon, Edward B

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center

Cancer immunology research, 2018-03, Vol.6 (3), p.288-294

2018

Link zum Volltext

Verfügbarkeit prüfen

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Journal of clinical oncology, 2019-10, Vol.37 (28), p.2518-2527

2019

Link zum Volltext

Verfügbarkeit prüfen

Highlights in non-small cell lung cancer from the IASLC 2023 World Conference on Lung Cancer: commentary

Clinical advances in hematology & oncology, 2023-10, Vol.21 Suppl 5 (10), p.13-16

Garon, Edward B

2023

Link zum Volltext

Verfügbarkeit prüfen

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth

Molecular cancer therapeutics, 2013-06, Vol.12 (6), p.890-900

2013

Link zum Volltext

Verfügbarkeit prüfen

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

Journal of thoracic oncology, 2021-02, Vol.16 (2), p.205-215

2021

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Journal of thoracic oncology, 2018-08, Vol.13 (8), p.1138-1145

2018

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-05, Vol.378 (22), p.2078-2092

2018

Link zum Volltext

Verfügbarkeit prüfen

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2013-03, Vol.8 (3), p.270-278

2013

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1992-1998

2023

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-05, Vol.372 (21), p.2018-2028

2015

Link zum Volltext

Verfügbarkeit prüfen

CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity

Journal for immunotherapy of cancer, 2023-09, Vol.11 (9), p.e006896

2023

Link zum Volltext

Verfügbarkeit prüfen

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.1718-1732

2021

Link zum Volltext

Verfügbarkeit prüfen

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2019-08, Vol.25 (16), p.5061-5068

2019

Link zum Volltext

Verfügbarkeit prüfen

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer

Clinical cancer research, 2021-10, Vol.27 (19), p.5258-5271

2021

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01

Journal of clinical oncology, 2023-10, Vol.41 (29), p.4678-4687

2023

Link zum Volltext

Verfügbarkeit prüfen

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Journal of clinical oncology, 2024-01, Vol.42 (2), p.180-191

2024

Link zum Volltext

Verfügbarkeit prüfen

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer

Clinical cancer research, 2021-08, Vol.27 (16), p.4566-4573

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

KollektionElectronic Journals Library - Freely accessible e-journals

ThemaCarcinoma, Non-Small-Cell Lung - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Humans
(39)
Lung Neoplasms - Drug Therapy
(36)
Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Oncology
(25)
Female
(20)
Male
(18)
Aged
(17)
Middle Aged
(17)
Adult
(16)
Carcinoma, Non-Small-Cell Lung - Pathology
(15)
Lung Neoplasms - Pathology
(14)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(12)
Carcinoma, Non-Small-Cell Lung - Genetics
(12)
Lung Neoplasms - Genetics
(12)
Mutation
(12)
Aged, 80 And Over
(11)
Lung Cancer
(10)
Respiratory System
(10)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

Osimertinib plus Ramucirumab: The Best of Both Worlds?

Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Highlights in non-small cell lung cancer from the IASLC 2023 World Conference on Lung Cancer: commentary

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer

Aktive Filter

Suchergebnisse filtern